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Background/aim: The coronavirus disease 2019 (COVID-19) mostly manifests with fever, shortness of breath, and cough, has also been
found to cause some neurological symptoms, such as anosmia and ageusia. The aim of the study was to present the magnetic resonance
imaging (MRI) findings of patients with anosmia-hyposmia symptoms and to discuss potential mechanisms in light of these findings.
Materials and methods: Of the 2412 patients diagnosed with COVID-19-related pneumonia (RT-PCR at least once + clinically
confirmed) between March and December 2020, 15 patients underwent olfactory MRI to investigate the cause of ongoing anosmia/
hyposmia symptoms were included in the study.
Results: Eleven (73.3%) patients were female and four (26.7%) were male. A total of eight patients (53.3%) showed thickening in the
olfactory cleft region, where the olfactory epithelium is located. In nine patients (60%), enhancement was observed in the olfactory
cleft region. Diffusion-weighted imaging showed restricted diffusion in three patients (20%) (corpus callosum splenium in one patient,
thalamus mediodorsal nucleus in one patient, and mesencephalon in one patient).
Conclusion: This study revealed that there is a relationship between anosmia and MRI findings. Larger studies can enlighten the
pathophysiological mechanism and shed light on both diagnosis and new treatments.
Key words: COVID-19, anosmia, magnetic resonance imaging

1. Introduction
The coronavirus disease 2019 (COVID-19), which started
spreading in December 2019, rapidly became a pandemic.
The disease, which mostly manifests with fever, shortness
of breath, and cough, has also been found to cause
some neurological symptoms, such as anosmia, ageusia,
headache, and confusion [1].
Although it varies in various publications, a significant
portion (5%–68%) of COVID-19-positive patients have
been shown to have symptoms related to the sense of smell
and taste [2–4]. In fact, a study showed that almost all
COVID-19 patients had loss of sense of smell at a stage
close to the end of the acute recovery period, albeit at
different levels [5]. Moreover, while this loss was temporary
in many patients, in some patients, it was irreversible [6].
It has been observed that olfactory dysfunction may occur
before general symptoms, as well as during the course of
the disease or following other symptoms [7].

Studies showing that the viral load was more intense
in the nasal mucosa than the throat suggested that the
nasal epithelium might be an important location for
the infection to start and for the virus to proliferate and
spread [8]. Similar to severe acute respiratory syndromeassociated coronavirus (SARS-CoV), the current virus
has also been shown to utilize angiotensin-converting
enzyme-2 (ACE2) on the cell surface as a receptor to enter
the cell [9]. Immunohistochemical studies have revealed
that these enzymes are found in the nasal and bronchial
epithelium [10]. This information suggests that the
effects on the nasal mucosa and the olfactory epithelium
in the superior nasal meatus of SARS-CoV2 may be
the mechanisms causing smell-related symptoms, but
this still does not explain why in COVID-19, the smelltaste disorder is much more frequent than SARS-CoV
infections that use a similar mechanism to enter the cell
or other infections, such as influenza that cause smell and
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taste disorder through upper respiratory tract infections;
thus, the true mechanism of the new virus has not yet been
fully elucidated [11].
In some published articles, COVID-19 has been shown
to involve the central nervous system, cause posterior
reversible encephalopathy syndrome-like findings in the
brain, or lead to the development of acute necrotizing
encephalopathy [12]. In addition, in a published case
report, a patient with anosmia symptom presented with
signal changes on brain MRI images [13]. Moreover,
studies have reported that SARS-CoV infections cause
neuronal death, especially the death of the brain stem [14].
In light of this information, another hypothesis is that in
COVID-19, smell and taste disorders may occur due to
central involvement.
Imaging methods play an important role in clarifying
these mechanisms and better understanding COVID-19
infections. The aim of the study was to present the MRI
findings of COVID-19 patients with anosmia-hyposmia
symptoms and to discuss potential mechanisms in light of
these findings.
2. Materials and methods
For this retrospective study, approval was obtained from
the ethical committee of our institution.
2.1. Patient selection
Of the 2412 patients diagnosed with COVID-19 pneumonia
(confirmed by a minimum of one positive RT-PCR test
+ clinical findings) between March and December 2020
who underwent olfactory MRI to investigate the cause of
the ongoing anosmia/hyposmia symptoms were included
in the study. The sino-nasal outcome test -22 (SNOT22) questionnaire, which was validated in the Turkish
population, was used for smell and taste assessment [15].
2.2. MRI examinations
MRI was performed with a 1.5-T system (Signa Voyager;
GE Healthcare, Milwaukee, WI, USA). The image
acquisition protocol included (1) 3 mm-thick T2-weighted
images without interslice gap in the coronal plane covering
the whole brain using the fast spin-echo sequence (TR
2,430 ms; TW = 107 ms); (2) 5 mm-thick diffusionweighted images with a 1-mm interslice gap in the axial
plane covering the whole brain (TR 6400, TE = 98 ms,
b values 0 and 1,000 s/mm2), and (3) 0.6 mm-thick 3D
FIESTA-C images (TR: 5.4, TE: 2.1 ms, FOV 150 mm ×
100 mm, 146 axial slices), and 0.6 mm-thick precontrast
and postcontrast 3D T1-weighted BRAVO images (TR:
1900, TE: 2.55 ms, FOV 150 mm × 100 mm, 146 axial
slices).
2.3. Image analysis
All imaging findings were evaluated simultaneously,
including complete nasal obstruction, superior orbital

meatus obstruction, and sinonasal mucosa, excessive
enhancement in postcontrast images, pathological signal
change in T2-weighted images in the brain, and diffusion
restriction in the brain. Orbital cleft thickness was
evaluated on coronal T2-weighted images. The evaluation
of the images was independently undertaken by two
radiologists with the prediagnosis of COVID-19-related
pneumonia. If their initial opinions differed, a consensus
was reached.
2.4. Statistical analysis
MedCalc (ver. 12, Ostend, Belgium) was used for statistical
analysis. The descriptive statistics were given as median
(minimum–maximum) and mean ± standard deviation.
Categorical variables were expressed as frequencies and
percentages.
3. Results
A total of 15 patients were included in the study. Eleven
(73.3%) of the patients were female and 4 (26.7%) were
male. The mean age of the patients was 25.1 ± 11.4 years.
When the pneumonia findings were evaluated, disease
severity was mild in 13 patients (86.6%) and moderate
in two patients (13.4%). The average length of hospital
stay was 3 ± 1.9 days. A total of eight patients (53.3%)
showed thickening in the olfactory cleft region, where
the olfactory epithelium is located. In five of these
patients (62.5%) thickening was bilateral (Figures 1a and
1b), while in three patients, thickening was unilateral
(37.5%) (Figures 2a and 2b). In nine patients (60%),
enhancement was observed in the olfactory cleft region.
Enhancement was bilateral in five patients (55.5%), and
unilateral in four patients (44.5%). Diffusion-weighted
imaging was restricted in three patients (20%) (in the
corpus callosum splenium, thalamus mediodorsal
nucleus and mesencephalon in one patient each). In
these three patients, T2 signal was also increased in areas
with restricted diffusion. However, no T2 signal changes
were detected in the brain in other patients. In one of our
patients, the smell disorder appeared as a symptom of mild
encephalitis/encephalopathy with a reversible splenial
lesion (MERS) (Figures 3a, 3b and 4a, 4b). None of the
patients had nasal obstruction. While only one patient
(6.6%) had a runny nose, five (33.3%) had postnasal drip
and six (40%) had a sore throat. Anosmia was present
in 10 patients (66.6%) and hyposmia in five patients
(33.4%). The mean symptom duration of the patients was
11.4 ± 6.3 days. Complete improvement was achieved in
12 patients (80%), and partial in three patients (20%).
The most common symptom related to the sense of taste
was hypogeusia detected in seven patients (46.6%). Three
patients (20%) had ageusia (Table).

1507

ÇETİN et al. / Turk J Med Sci

1

Figure 1. Coronal pre- (a) and postcontrast (b) T1-weighted image showing thickening
and enhancement in the bilateral olfactory cleft and mucosa.

1

Figure 2. Coronal pre- (a) and postcontrast (b) T1-weighted image showing thickening
and enhancement in the right olfactory cleft and mucosa.

1

Figure 3. Axial diffusion-weighted image (a) (b = 1000) and the
apparent diffusion coefficient (ADC) map (b) showing a diffusionrestricted lesion in the splenium of the corpus callosum (arrow).

1

Figure 4. The control images of the same patient, axial diffusionweighted image (a) (b = 1000) and the apparent diffusion
coefficient (ADC) map (b), shows that the lesions disappeared.
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Table. Patient data.

Age/Sex

Diffusion-weighted imaging
features

Olfactory cleft
thickening

Enhancement in the
olfactory cleft

Sense of smell

Sense of taste

30/F

-

Bilateral

Bilateral

Anosmia

Ageusia

29/F

-

Bilateral

Bilateral

Hyposmia

Hypogeusia

37/M

-

Unilateral

Unilateral

Anosmia

Normal

27/F

Mediodorsal nucleus

Bilateral

Bilateral

Anosmia

Normal

54/F

-

-

-

Hyposmia

Normal

27/F

-

-

-

Anosmia

Ageusia

27/F

-

Bilateral

Bilateral

Anosmia

Normal

21/F

-

-

-

Hyposmia

Hypogeusia

36/F

-

Unilateral

Unilateral

Anosmia

Normal

17/F

-

-

-

Anosmia

Hypogeusia

17/M

-

Bilateral

Bilateral

Anosmia

Hypogeusia

15/F

-

-

-

Anosmia

Ageusia

11/F

-

Unilateral

Unilateral

Hyposmia

Hypogeusia

14/M

Splenium of the corpus callosum -

-

Hyposmia

Hypogeusia

15/M

Mesencephalon

Unilateral

Anosmia

Hypogeusia

-

4. Discussion
In approximately half of the patients (8/15), we observed
unilateral (3/8) or bilateral (5/8) thickening in the
olfactory cleft region and intense contrast enhancement in
this area in nine patients. In addition, in three patients,
we found restricted diffusion findings in the corpus
callosum splenium, thalamus mediodorsal nucleus and
mesencephalon in diffusion-weighted images. In five of
the 15 patients, we did not find any pathological findings
on MRI.
Olfactory system disorder is a very common condition
in COVID-19 infection. Although many agents of upper
respiratory tract infections (parainfluenza, rhinovirus,
influenza, and coronavirus) are known to cause loss of
smell due to olfactory epithelial involvement, this symptom
has been reported to be more common in COVID-19
patients [4,16]. In addition, unlike upper respiratory
infections, COVID-19 also rarely shows upper respiratory
symptoms [17]. As in our study, it was very interesting to
observe anosmia without nasal obstruction in COVID-19
patients. None of our patients had nasal obstruction
clinically or radiologically. In addition, although some of
the patients with radiological olfactory cleft involvement
had narrowing of this region, only a small portion of
olfactory cleft obstruction was observed (2/15). Although
the loss of sense of smell due to viral factors is mostly
recovered in the early period, it is known to last up to two
years in some patients [18]. In a recent study of 23 patients
by Kandemirli et al., diffusely increased signal intensity,

scattered hyperintense foci or microhemorrhages were
observed in 91.3% of the patients [19]. In a recent study
by Chetrit et al., bilateral obstruction of the olfactory clefts
was detected in 47% of COVID-19 patients with suddenonset total loss of smell [20]. In all of the current study
patients, inflammatory thickening and increased T2 signal
were observed in the nasal mucosa at the olfactory cleft.
In a study by Strauss et al., the normalized olfactory bulb
T2 FLAIR (fluid-Attenuated inversion recovery) signal
intensity value was found to be higher in patients with
anosmia. However, in that study, only 4 of 12 patients had
intraneural T2 signal hyperintensity on 3D T2 FLAIR [21].
There are very few imaging studies on the loss of sense
of smell developing during or after upper respiratory tract
infections. In a study by Muller et al. evaluating patients
with olfactory dysfunction caused by upper respiratory
infections, it was observed that the volume of the olfactory
bulbus was greater in patients with hyposmia than in
those with complete anosmia [22]. Yao et al. also showed
that the olfactory bulb volume decreased in patients
with postviral smell loss [23]. Chung et al. investigated
whether there was atrophy by evaluating the olfactory bulb
volume in patients, and whether there was neuropathy by
evaluating the olfactory bulb signal intensity in FLAIR
MRI images. In postviral cases, there were signs of atrophy
and neuropathy in patients with both anosmia/hyposmia
and normosmia, and there was no significant difference
between these two groups [24]. However, in that study, the
number of postviral patients was very low.
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The cell surfaces of proteins/receptors to which viruses
attach and the mechanisms that allow viruses to enter these
cells are the main factors that determine the involvement
and spread regions of infections. The viral load in nasal
swabs being shown to be higher than the samples taken
from the throat indicates that the nasal mucosa can be very
effective in the introduction of the SARS-CoV2 virus and
its spread from person to person [25]. Subsequent studies
have shown that the spike protein binds to the ACE2
receptor on the cell surface and that S protein and ACE2
affinity is the major factor in virus proliferation and disease
progression [9]. Infection of olfactory sustentacular cells
in the olfactory cleft mucosa that does not allow the scent
particles to reach the olfactory nerve may be one of the
mechanisms preventing smell. However, in a study of mice
with another human coronavirus, virus antigens were
observed three days after virus infection in the olfactory
bulb, and seven days later, the olfactory symptoms were
found not be limited to mucosal involvement. This
is supported by our results revealing thickening and
enhancement in the olfactory cleft although these findings
were not present in most of the remaining mucosal tissue
and sinuses. In addition, intense enhancement without
significant mucosal thickening in the olfactory epithelium
was seen in one patient, which could indicate that the
effect is not only at the mucosal level. Politi et al. recently
published the report of a case with anosmia, in which there
were hyperintense signal changes in FLAIR MRI images
in the gyrus rectus that disappeared after the patient’s
symptoms regressed, suggesting that COVID-related odor
disorders may also be associated with central involvement
[13].
In one of our patients, there was hyperintensity and
restricted diffusion in the T2-weighted image in the
corpus callosum splenium without abnormal thickening
or enhancement in the nasal olfactory cleft. This patient
had no neurological symptom other than headache
accompanying hyposmia. In addition, the patient had no
respiratory symptoms. The control images obtained after
the patient’s odor symptom disappeared (on the 17th day)
no longer showed hyperintensity and restricted diffusion
on the T2-weighted image. Based on these findings,
the patient was diagnosed with mild encephalitis/
encephalopathy with a reversible splenial lesion (MERS).
Transient lesions of the corpus callosum can occur for
many reasons, such as multiple sclerosis, trauma, drug
use, and neoplasms, as well as viral etiology. In MERS,
usually presenting with neurological symptoms, such as
loss of consciousness, headache, and speech disorders
after prodromal symptoms (e.g., fever, vomiting and
diarrhea), the complete disappearance of neurological and
MRI findings is typical [26]. It is interesting to note that in
our patient, the symptoms were limited to headache and
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olfactory findings. Since the corpus callosum is a structure
consisting of fibers that provide interhemispheric
connection, smell-related symptoms rarely expected in
these lesions. However, in a study of patients with corpus
callosum agenesis, some patients were shown to have smell
and taste impairment [27]. In addition, in an influenzaassociated case of MERS reported by Takatsu et al., a
significant decrease was observed in the sense of smell, as
in our case, in addition to the change of consciousness [28].
To the best of our knowledge, the current report describes
the first pediatric MERS case associated with COVID-19.
The thalamus is a structure associated with many
functions, such as sensory perception, attention, sleep,
and cognitive and behavioral memory. Although olfactory
sensory neurons are not directly related to the thalamus,
the mediodorsal thalamic nucleus is known to have
afferent and efferent connections with both primary and
secondary olfactory domains [29]. However, the effect
of the thalamus on the olfactory system is not yet fully
understood [30]. In our study, diffusion restriction in
the thalamus mediodorsal nucleus was observed in one
patient. Bilateral olfactory cleft involvement was also
present in this patient. This patient did not present with
additional neurological findings, and her olfactory deficit
may have been due to mediodorsal nucleus involvement
or olfactory cleft involvement. In a previous COVID-19
case with acute necrotizing hemorrhagic encephalopathy,
bilateral thalamus involvement was also present [12]. Our
patient had unilateral thalamic involvement, and there
were no noteworthy imaging findings in other areas of the
brain.
In the patient population in our study, it was observed
that the ratios of young age and women were higher.
Although different rates of age and sex are seen in
previous studies conducted, COVID-19 patients with
odor symptoms are mostly young, and this disease is more
common in women according to a multicultural study
conducted by Lechien et al. [7].
In one of our patients, we observed a focal restricted
diffusion finding at the level of the superior cerebellar
pedicle-mesencephalon junction. Although the superior
cerebellar pedicle mainly contains fibers belonging to the
cerebellothalamic tract, it is associated with the ventral
nuclei of the thalamus, and there is no information
related to the sense of smell. Therefore, in light of current
information, we do not think that the restricted diffusion
finding in this patient was directly related to the sense of
smell. However, this finding is very important in terms of
showing the central nervous system involvement of the
disease. We consider that the deterioration in the sense
of smell might be central in this case, in which we did
not detect olfactory cleft involvement. In addition, since
we do not know at which stage the neural involvement of
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the disease was at the time of acquiring the image, active
inflammation in the areas related to the sense of smell
may not have been displayed at the time when it exhibited
restricted diffusion findings.
There were some limitations to our study. The first was
the small number of patients included in the study, and the
second was the retrospective nature of the research. More
comprehensive and prospective studies should be planned
on this subject.
Loss of sense of taste and smell has become increasingly
important diagnostic findings for COVID-19. However,
the subjective nature of this finding creates difficulties in
explaining the pathophysiology. Our study revealed that
there is a relationship between loss of sense of taste and
smell and MRI findings. Furthermore, in one of our patients,
the smell disorder appeared as a symptom of MERS, and

to our knowledge, this is the first reported SARS-CoV2related pediatric MERS case. Larger studies in the future
can enlighten the pathophysiological mechanism and shed
light on both diagnosis and new treatments.
Acknowledgment/disclaimer/conflict of interest
The authors declare no conflict of interests.
The authors declared that this study has received no
financial support.
Informed consent
This retrospective study has been approved by
the local ethics committee (Sakarya University,
71522473/050.01.04/203) and conducted in accordance
with the Declaration of Helsinki. Informed consent was
waived because of the retrospective nature of the study.

References
1.

Ates OF, Taydas O, Dheir H. Thorax magnetic resonance
imaging findings in patients with coronavirus disease
(covid-19). Academic Radiology 2020; 27 (10): 1373-1378. doi:
10.1016/j.acra.2020.08.009

8.

Sungnak W, Huang N, Bécavin C, Berg M, Queen R et al. Sarscov-2 entry factors are highly expressed in nasal epithelial cells
together with innate immune genes. Nature Medicine 2020; 26
(5): 681-687. doi: 10.1038/s41591-020-0868-6

2.

Lüers JC, Klußmann JP, Guntinas-Lichius O. [the covid-19
pandemic and otolaryngology: What it comes down to?].
Laryngo- rhino- otologie 2020; 99 (5): 287-291. doi: 10.1055/a1095-2344

9.

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler
T et al. Sars-cov-2 cell entry depends on ace2 and tmprss2 and
is blocked by a clinically proven protease inhibitor. Cell 2020;
181 (2): 271-280.e278. doi: 10.1016/j.cell.2020.02.052

3.

Bagheri SH, Asghari A, Farhadi M, Shamshiri AR, Kabir A et al.
Coincidence of covid-19 epidemic and olfactory dysfunction
outbreak in Iran. Medical Journal of the Islamic Republic of
Iran 2020; 34: 62. doi: 10.34171/mjiri.34.62

10.

4.

Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M et
al. Self-reported olfactory and taste disorders in patients
with severe acute respiratory coronavirus 2 infection: A
cross-sectional study. Clinical Infectious Diseases : an official
publication of the Infectious Diseases Society of America 2020;
71 (15): 889-890. doi: 10.1093/cid/ciaa330

Bertram S, Heurich A, Lavender H, Gierer S, Danisch S et al.
Influenza and sars-coronavirus activating proteases tmprss2
and hat are expressed at multiple sites in human respiratory
and gastrointestinal tracts. PloS one 2012; 7 (4): e35876. doi:
10.1371/journal.pone.0035876

11.

de Haro-Licer J, Roura-Moreno J, Vizitiu A, GonzálezFernández A, González-Ares JA. Long term serious olfactory
loss in colds and/or flu. Acta Otorrinolaringologica Espanola
2013; 64 (5): 331-338. doi: 10.1016/j.otorri.2013.04.003

5.

Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi
A, Tabarsi P et al. Smell dysfunction: A biomarker for covid-19.
International Forum of Allergy & Rhinology 2020; 10 (8): 944950. doi: 10.1002/alr.22587

12.

Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S et al. Covid19-associated acute hemorrhagic necrotizing encephalopathy:
Imaging features. Radiology 2020; 296 (2): E119-e120. doi:
10.1148/radiol.2020201187

6.

Beltrán-Corbellini Á, Chico-García JL, Martínez-Poles
J, Rodríguez-Jorge F, Natera-Villalba E et al. Acute-onset
smell and taste disorders in the context of covid-19: A pilot
multicentre polymerase chain reaction based case-control
study. European Journal of Neurology 2020; 27 (9): 1738-1741.
doi: 10.1111/ene.14273

13.

Politi LS, Salsano E, Grimaldi M. Magnetic resonance imaging
alteration of the brain in a patient with coronavirus disease
2019 (covid-19) and anosmia. JAMA Neurology 2020; 77 (8):
1028-1029. doi: 10.1001/jamaneurol.2020.2125

14.

Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S.
Severe acute respiratory syndrome coronavirus infection
causes neuronal death in the absence of encephalitis in mice
transgenic for human ace2. Journal of Virology 2008; 82 (15):
7264-7275. doi: 10.1128/jvi.00737-08

15.

Cakir Cetin A, Kumus O, Keskinoglu P, Sutay S, Ecevit MC.
Turkish validation of the sino-nasal outcome test-22. Clinical
Otolaryngology 2019; 44 (4): 557-564. doi: 10.1111/coa.13332

7.

Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le
Bon SD et al. Olfactory and gustatory dysfunctions as a clinical
presentation of mild-to-moderate forms of the coronavirus
disease (covid-19): A multicenter european study. European
Archives of Oto-rhino-laryngology 2020; 277 (8): 2251-2261.
doi: 10.1007/s00405-020-05965-1

1511

ÇETİN et al. / Turk J Med Sci
16.

Soler ZM, Patel ZM, Turner JH, Holbrook EH. A primer
on viral-associated olfactory loss in the era of covid-19.
International Forum of Allergy & Rhinology 2020; 10 (7): 814820. doi: 10.1002/alr.22578

24.

Chung MS, Choi WR, Jeong HY, Lee JH, Kim JH. Mr imagingbased evaluations of olfactory bulb atrophy in patients with
olfactory dysfunction. American Journal of Neuroradiology
2018; 39 (3): 532-537. doi: 10.3174/ajnr.A5491

17.

Yang X, Yu Y, Xu J, Shu H, Xia J et al. Clinical course and
outcomes of critically ill patients with sars-cov-2 pneumonia in
wuhan, china: A single-centered, retrospective, observational
study. The Lancet Respiratory Medicine 2020; 8 (5): 475-481.
doi: 10.1016/s2213-2600(20)30079-5

25.

Özdemir M, Taydaş O, Öztürk MH. Covid-19 enfeksiyonunda
toraks bilgisayarlı tomografi bulguları. Journal of Biotechnology
and Strategic Health Research 2020; 4: 91-96. doi: 10.34084/
bshr.725584

18.

Duprez TP, Rombaux P. Imaging the olfactory tract (cranial
nerve #1). European Journal of Radiology 2010; 74 (2): 288298. doi: 10.1016/j.ejrad.2009.05.065

26.

Tada H, Takanashi J, Barkovich AJ, Oba H, Maeda M et al.
Clinically mild encephalitis/encephalopathy with a reversible
splenial lesion. Neurology 2004; 63 (10): 1854-1858. doi:
10.1212/01.wnl.0000144274.12174.cb

19.

Kandemirli SG, Altundag A, Yildirim D, Tekcan Sanli DE,
Saatci O. Olfactory bulb mri and paranasal sinus ct findings in
persistent covid-19 anosmia. Academic Radiology 2021; 28 (1):
28-35. doi: 10.1016/j.acra.2020.10.006

27.

20.

Chetrit A, Lechien JR, Ammar A, Chekkoury-Idrissi Y,
Distinguin L et al. Magnetic resonance imaging of covid-19
anosmic patients reveals abnormalities of the olfactory bulb:
Preliminary prospective study. Journal of Infection 2020; 81
(5): 816-846. doi: 10.1016/j.jinf.2020.07.028

Demopoulos C, Arroyo MS, Dunn W, Strominger Z, Sherr EH
et al. Individuals with agenesis of the corpus callosum show
sensory processing differences as measured by the sensory
profile. Neuropsychology 2015; 29 (5): 751-758. doi: 10.1037/
neu0000165

28.

Takatsu H, Ishimaru N, Ito M, Kinami S. Mild encephalitis/
encephalopathy with a reversible splenial lesion in an adult
patient with influenza. Internal Medicine (Tokyo, Japan) 2017;
56 (22): 3093-3095. doi: 10.2169/internalmedicine.8997-17

21.

Strauss SB, Lantos JE, Heier LA, Shatzkes DR, Phillips CD.
Olfactory bulb signal abnormality in patients with covid-19
who present with neurologic symptoms. American Journal of
Neuroradiology 2020. doi: 10.3174/ajnr.A6751

29.

Illig KR. Projections from orbitofrontal cortex to anterior
piriform cortex in the rat suggest a role in olfactory information
processing. The Journal of Comparative Neurology 2005; 488
(2): 224-231. doi: 10.1002/cne.20595

22.

Mueller A, Rodewald A, Reden J, Gerber J, von Kummer R et
al. Reduced olfactory bulb volume in post-traumatic and postinfectious olfactory dysfunction. Neuroreport 2005; 16 (5):
475-478. doi: 10.1097/00001756-200504040-00011

30.

Courtiol E, Wilson DA. The olfactory thalamus: Unanswered
questions about the role of the mediodorsal thalamic nucleus
in olfaction. Frontiers in Neural Circuits 2015; 9: 49. doi:
10.3389/fncir.2015.00049

23.

Yao L, Yi X, Pinto JM, Yuan X, Guo Y et al. Olfactory cortex
and olfactory bulb volume alterations in patients with postinfectious olfactory loss. Brain Imaging and Behavior 2018; 12
(5): 1355-1362. doi: 10.1007/s11682-017-9807-7

1512

